SCHEMBL7077896

SCHEMBL7077896

COc1ccc(S(=O)(=O)CC(CCCN2C(=O)c3ccccc3C2=O)C(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.60
MMP9 P14780 8/20 0.60
HSD17B10 Q99714 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
ALDH1A1 P00352 3/20 0.48
MMP3 P08254 3/20 0.48
MMP13 P45452 2/20 0.48
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
MMP1 P03956 2/20 0.47
MMP14 P50281 1/20 0.47
MMP8 P22894 1/20 0.46
POLB P06746 1/20 0.46
APEX1 P27695 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CASP3 P42574 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7077886 0.94 MMP2 (0.66) MMP2MMP9HSD17B10MEN1KMT2A
SCHEMBL6578094 0.85 MMP2 (0.65) MMP2MMP9ALDH1A1MMP3MMP13
SCHEMBL7075454 0.85 POLB (0.46) MMP2MMP9HSD17B10KMT2AALDH1A1
SCHEMBL7226591 0.80 MMP2 (0.60) MMP2MMP9MMP3MMP13MMP1
SCHEMBL7077710 0.80 MMP2 (0.70) MMP2MMP9HSD17B10ALDH1A1MMP3
SCHEMBL7073583 0.80 MMP2 (0.56) MMP2MMP9HSD17B10MEN1KMT2A
SCHEMBL6377986 0.79 HTT (0.57) MMP2MMP9MEN1KMT2AALDH1A1
SCHEMBL7956006 0.78 MMP2 (0.64) MMP2MMP9MMP3MMP13MMP1
SCHEMBL7080824 0.77 MMP13 (0.48) MMP2MMP9ALDH1A1MMP3MMP13
SCHEMBL6378307 0.77 HTT (0.59) MMP2MMP9MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030207889-A1 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity OWEN DAVID ALAN (GB) 2003-11-06 US claimed
US-20030207889-A1 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity OWEN DAVID ALAN (GB) 2003-11-06 US disclosed
US-6566384-B1 For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response DARWIN DISCOVERY LTD. (GB) 2003-05-20 US disclosed
US-6118001-A ANTICANCER AGENT; ANTIARTHRITIC AGENT DARWIN DISCOVERY, LTD. (GB) 2000-09-12 US disclosed
EP-0968182-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY Darwin Discovery Limited (GB) 2000-01-05 EP disclosed
WO-1998005635-A1 HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY DARWIN DISCOVERY LIMITED (GB) 1998-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207889-A1 Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity MMP13, MMP2, MMP9 MMP2 2/4885MMP9 3/4885HSD17B10 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.